Citigroup Inc. reiterated their sell rating on shares of Smith & Nephew plc (LON:SN) in a report issued on Friday morning. The firm currently has a GBX 1,160 ($15.25) target price on the stock.

SN has been the subject of several other reports. J P Morgan Chase & Co lifted their price objective on Smith & Nephew plc from GBX 1,280 ($16.83) to GBX 1,361 ($17.89) and gave the company a neutral rating in a report on Monday, July 31st. HSBC Holdings plc reaffirmed a hold rating and issued a GBX 1,320 ($17.35) price objective on shares of Smith & Nephew plc in a report on Monday, July 10th. Credit Suisse Group reaffirmed a neutral rating and issued a GBX 1,280 ($16.83) price objective on shares of Smith & Nephew plc in a report on Friday, July 28th. Jefferies Group LLC lifted their price objective on Smith & Nephew plc from GBX 1,350 ($17.75) to GBX 1,515 ($19.92) and gave the company a buy rating in a report on Friday, July 28th. Finally, Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,200 ($15.78) price objective on shares of Smith & Nephew plc in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of GBX 1,289.25 ($16.95).

Shares of Smith & Nephew plc (LON SN) opened at 1370.00 on Friday. The company’s market capitalization is GBX 12.00 billion. The firm has a 50-day moving average price of GBX 1,366.25 and a 200-day moving average price of GBX 1,325.75. Smith & Nephew plc has a 12 month low of GBX 1,064.91 and a 12 month high of GBX 1,412.00.

ILLEGAL ACTIVITY NOTICE: “Smith & Nephew plc (SN) Stock Rating Reaffirmed by Citigroup Inc.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/10/smith-nephew-plc-sn-stock-rating-reaffirmed-by-citigroup-inc.html.

The firm also recently declared a dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Thursday, October 5th will be paid a $0.12 dividend. The ex-dividend date is Thursday, October 5th. This represents a dividend yield of 0.72%.

In other Smith & Nephew plc news, insider Virginia Bottomley purchased 223 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were bought at an average price of GBX 1,380 ($18.14) per share, for a total transaction of £3,077.40 ($4,046.02).

About Smith & Nephew plc

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew plc (LON:SN)

Receive News & Stock Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related stocks with our FREE daily email newsletter.